Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -598.7%
March 31, 2026 -742.4%
December 31, 2025 -763.8%
September 30, 2025 -1.70K%
June 30, 2025 -1.54K%
March 31, 2025 -621.1%
December 31, 2024 -312.7%
September 30, 2024 -780.9%
June 30, 2024 -256.6%
March 31, 2024 -129.0%
December 31, 2023 -257.3%
September 30, 2023 -470.5%
June 30, 2023 -483.3%
March 31, 2023 -54.36%
December 31, 2022 -517.4%
September 30, 2022 -639.4%
June 30, 2022 -1.05K%
March 31, 2022 -2.21K%
December 31, 2021 -969.7%
September 30, 2021 -980.3%
June 30, 2021 -2.18K%
March 31, 2021 -2.61K%
December 31, 2020 -1.49K%
September 30, 2020 -3.69K%
June 30, 2020 -1.97K%
Date Value
March 31, 2020
December 31, 2019 -393.7%
September 30, 2019 -835.8%
June 30, 2019 -437.1%
March 31, 2019 -1.68K%
December 31, 2018 -1.11K%
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017
September 30, 2017
June 30, 2017 -53.09%
March 31, 2017 -19.48%
December 31, 2016 -30.78%
September 30, 2016 -128.4%
June 30, 2016 -125.9%
March 31, 2016 -81.19%
December 31, 2015 -48.38%
September 30, 2015 -209.6%
June 30, 2015 -124.1%
March 31, 2015 -113.5%
December 31, 2014 -188.3%
September 30, 2014 -82.23%
June 30, 2014 -226.9%
March 31, 2014 -81.54%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
ClearPoint Neuro, Inc. -104.2%
Abbott Laboratories 7.07%
AngioDynamics, Inc. -8.77%
Alphatec Holdings, Inc. -12.07%
AtriCure, Inc. 5.83%